{"task_id": "8b20156399b448e3", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 52/464)", "text": "5. For patients with NYHA III IV,\nHeart Failure\n37\n\n--- Page 59 ---\nTREATMENT ISSUES (CONT\u2019D)\nLVEF <35%, and on maximum treatment already.\nCaution in elderly and renal failure patients as higher\nrisk of hyperkalemia\nDIGOXIN (DIG 1997)\nhazard ratios for total mortal\nity 0.99 and mortality/hospitalization 0.92. Particu\nlarly useful for patients with both HF and atrial fibril\nlation,\nor\nsymptomatic\nHF\ndespite\nmaximum\ntreatment\nOVERALL APPROACH\ntreat underlying cause if\npossible.\nNon pharmacological\ntreatments\n(diet,\nexercise, smoking cessation) ! add ACE inhibitor\nfor all (or hydralazine/nitrates if renal failure, ARB if\ncough secondary to ACE inhibitor) ! add b blocker\nwhen euvolemic ! add spironolactone/eplerenone\nif NYHA III/IV ! add digoxin \u0007 ARB if still sympto\nmatic. If ejection fraction is <30 35% despite optimal\nmedical therapy, consider revascularization, implan\ntable cardioverter defibrillator, cardiac resynchroniza\ntion (if QRS is wide), and ventricular assist device/\nheart transplant\nSPECIFIC ENTITIES\nCAUSES OF FLASH PULMONARY EDEMA\ncardiac\n(ischemic heart disease, acute aortic regurgitation,\nacute mitral regurgitation, mitral stenosis/obstruc\ntion, arrhythmia), pulmonary (pulmonary embolism,\npneumonia), renal (bilateral renal artery stenosis),\nsystemic (hypertension crisis, fever, sepsis, anemia,\nthyroid disease)\nHYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY\n(HOCM)\n\u0002\nPATHOPHYSIOLOGY\nautosomal dominant condi\ntion with mutated cardiac sarcomere, leading to\nmassive ventricular hypertrophy (particularly sep\ntum). This results in left ventricular outflow tract\nSPECIFIC ENTITIES (CONT\u2019D)\nobstruction, mitral regurgitation, diastolic dysfunc\ntion, and subsequently myocardial ischemia and\novert heart failure. Cardiac arrhythmias may lead\nto sudden death (<1%/year). Other complications\ninclude atrial fibrillation and infective endocarditis\n\u0002\nRISK FACTORS FOR SUDDEN DEATH\nmajor risk factors\ninclude history of cardiac arrest (VF), sustained VT,\nunexplained syncope, non sustained VT on Holter,\nabnormal BP response on exercise test, left ventri\ncular wall thickness >30 mm, and family history of\nsudden death. Minor risk factors include left ventri\ncular outflow obstruction (gradient \u000530 mmHg),\nmicrovascular obstruction, and high risk genetic\ndefect\n\u0002\nCLINICAL\nFEATURES\nmost\nare\nasymptomatic\nalthough dyspnea, chest pain, syncope, and sudden\ndeath may develop. Family history should be\nobtained. Physical findings include brisk carotid\nupstroke, bifid carotid pulse, double apical impulse,\nsystolic ejection murmur (LLSB, louder with stand\ning and Valsalva) \u0007 mitral regurgitation murmur\n\u0002\nDIAGNOSIS\nechocardiogram (septal thickening,\nsystolic anterior motion of mitral valve). Further\nworkup includes 48 h holter monitor and exercise\ntesting annually\n\u0002\nTREATMENTS\navoidance (dehydration and stren\nuous exercise), medical (b blockers and non dihy\ndropyridine calcium channel blockers as first line,\ndisopyramide as second line), interventional/sur\ngical (septal myomectomy, alcohol septal ablation,\ndual chamber pacing), prophylaxis (implantable\ncardioverter defibrillator for high risk patients to\nprevent sudden cardiac death, anticoagulation if\natrial fibrillation)\nNEJM 2004 350:13\nDigoxin Intoxication\nCirculation 2004 109:24\nDIFFERENTIAL DIAGNOSIS\nOVERDOSE\nintentional, accidental (digoxin, fox\nglove, yellow oleander)\nDRUG INTERACTIONS\nquinidine, amiodarone,\nverapamil, diltiazem, tetracycline, erythromycin,\nrifampin, cyclosporine, SSRIs\nPHARMACOKINETICS\n\u0002\nOLD AGE, RENAL FAILURE\n\u0002\nCARDIAC\nischemia, myocarditis, cardiomyopa\nthy, amyloidosis, cor pulmonale\n\u0002\nMETABOLIC\nhypokalemia,\nhypomagnesemia,\nhypernatremia,\nhypercalcemia,\nhypoxemia,\nacid base imbalance\nPATHOPHYSIOLOGY\nDIGOXIN LEVEL\nmeasurement of serum levels is\nnot routinely necessary as dosing can usually be\ntitrated according to clinical and hemodynamic\neffects. When measured, serum level should be col\nlected at 12 24 h after the last dose (post distribution\nphase). While the upper normal limit is 2.6 nmol/L\n[2.0 ng/mL], higher digoxin levels may be seen in\nasymptomatic patients. Low dose digoxin, resulting\nin serum levels 0.5 0.9 nmol/L [0.4 0.7 ng/mL] is\nassociated with possible survival benefit compared\nto \u00051 nmol/L [\u00050.78 ng/mL] in HF patients\nMECHANISM\ndigitalis acts by inhibiting the mem\nbrane bound Na/K ATPase transport system. This\n38\nDigoxin Intoxication", "text_length": 4371, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 52/464)", "type": "chunk", "chunk_index": 51, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.304432", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.305289", "status": "complete", "chunks_added": 3}